UroGen Pharma Overview
UroGen Pharma (URGN) has a PEG ratio of 30.08, above the Healthcare sector average of 11.64.
Get informed when a big investor buys or sells
+ Follow30.08
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for URGN is 30.08. That is above the Healthcare sector average of 11.64. Investors often review this figure alongside UroGen Pharma's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, URGN currently prints 30.08 for PEG ratio, while the sector average sits near 11.64. That is roughly 158.4% above the sector mean. Large gaps often invite a closer look at UroGen Pharma's growth, margins, and balance sheet.
A PEG ratio of 30.08 for UroGen Pharma is not 'good' or 'bad' on its own. Compare it with the peer average (11.64) and with URGN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting URGN's PEG ratio (30.08), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack UroGen Pharma's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
